Analysis: Gilead an increasingly attractive takeover target

09/2/2008 | San Francisco Chronicle

Gilead Sciences remains an attractive takeover target for major drugmakers because of its promising pipeline and consistent revenue, primarily from HIV medicines Viread, Truvada and Atripla. However, a takeover of the biotech firm may prove difficult because Gilead's growth strategy has always focused on "building a very strong independent company," Chief Operating Officer John Milligan said.

View Full Article in:

San Francisco Chronicle

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Behavioral Health Operations
Meridian Health Plan
Detroit, MI
Medical Director
Bend, OR
Clinical Appeals RN
Brooklyn, NY
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ